Chen TT - Search Results

1

Predicting analysis times in randomized clinical trials with cancer immunotherapy.

Chen TT. Chen TT. BMC Med Res Methodol. 2016 Feb 1;16:12. doi: 10.1186/s12874-016-0117-3. BMC Med Res Methodol. 2016. PMID: 26830911 Free PMC article.

2

Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?

Chen TT. Chen TT. Cancer Immunol Res. 2018 Mar;6(3):250-254. doi: 10.1158/2326-6066.CIR-17-0465. Cancer Immunol Res. 2018. PMID: 31343973 Review.

3

Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.

Mick R, Chen TT. Mick R, et al. Among authors: chen tt. Cancer Immunol Res. 2015 Dec;3(12):1292-8. doi: 10.1158/2326-6066.CIR-15-0260. Cancer Immunol Res. 2015. PMID: 26644449 Review.

4

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Schadendorf D, et al. Among authors: chen tt. J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9. J Clin Oncol. 2015. PMID: 25667295 Free PMC article.

5

Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.

Chen TT. Chen TT. J Natl Cancer Inst. 2015 Jun 25;107(9):djv156. doi: 10.1093/jnci/djv156. Print 2015 Sep. J Natl Cancer Inst. 2015. PMID: 26113579 Free PMC article.

6

Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.

Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Feng Y, et al. Among authors: chen tt. Clin Cancer Res. 2013 Jul 15;19(14):3977-86. doi: 10.1158/1078-0432.CCR-12-3243. Epub 2013 Jun 5. Clin Cancer Res. 2013. PMID: 23741070

7

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Maio M, et al. Among authors: chen tt. J Clin Oncol. 2015 Apr 1;33(10):1191-6. doi: 10.1200/JCO.2014.56.6018. Epub 2015 Feb 23. J Clin Oncol. 2015. PMID: 25713437 Free PMC article. Clinical Trial.

8

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.

Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ. Wolchok JD, et al. Among authors: chen tt. Cancer Immun. 2010 Oct 20;10:9. Cancer Immun. 2010. PMID: 20957980 Free PMC article. Clinical Trial.

9

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen TT, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M. Suciu S, et al. Among authors: chen tt. J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133. J Natl Cancer Inst. 2018. PMID: 28922786 Review.

10

Statistical issues and challenges in immuno-oncology.

Chen TT. Chen TT. J Immunother Cancer. 2013 Oct 21;1:18. doi: 10.1186/2051-1426-1-18. eCollection 2013. J Immunother Cancer. 2013. PMID: 24829754 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,050 results

Search Page

Filters